Apoptosis and melanoma: Molecular mechanisms

Journal of Pathology

Volumn 199, Issue 3, 2003, Pages 275-288

  Hussein, Mahmoud R ^a   Haemel, Anna K ^a   Wood, Gary S ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Anti apoptotic molecules; CMM; Cutaneous malignant melanoma; Pro apoptotic molecules; Programmed cell death

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; ENDOTHELIN; FAS ANTIGEN; FAS LIGAND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; INTEGRIN; MYC PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID; PROTEIN KINASE; PROTEIN MCL 1; PROTEIN P53; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; SURVIVIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL DEATH; DRUG TARGETING; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; MALIGNANT NEOPLASTIC DISEASE; MELANOMA CELL; MOLECULAR BIOLOGY; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN FAMILY; RECEPTOR DOWN REGULATION; REGULATORY MECHANISM; REVIEW; SKIN CANCER; TREATMENT PLANNING; TUMOR SUPPRESSOR GENE; ULTRAVIOLET IRRADIATION;

APOPTOSIS; GENES, BCL-2; GENES, P53; HUMANS; MELANOMA; SKIN NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037372013     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1300     Document Type: Review

References (121)

1. Wyllie AH. Apoptosis: an overview. Br Med Bull 1997; 53: 451-465.
2. Trauth BC, Klas C, Peters AM, et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989; 245: 301-305.
3. Lee SW, Ko YG, Bang S, Kim KS, Kim S. Death effector domain of a mammalian apoptosis mediator, FADD, induces bacterial cell death. Mol Microbiol 2000; 35: 1540-1549.
4. Weber CH, Vincenz C. A docking model of key components of the DISC complex: death domain superfamily interactions redefined. FEBS Lett 2001; 492: 171-176.
5. Martins LM, Iaccarino I, Tenev T, et al. The serine protease Omi/HtrA2 regulates apoptosis by binding XIAP through a reaper-like motif. J Biol Chem 2002; 277: 439-444.
6. Wu X, Deng Y. Bax and bh3-domain-only proteins in p53-mediated apoptosis. Front Biosci 2002; 7: D151-156.
7. Beere HM. Stressed to death: regulation of apoptotic signaling pathways by the heat shock proteins. Sci STKE 2001; 2001: RE1.
8. Hall PA, Meek D, Lane DP. p53: integrating the complexity. J Pathol 1996; 180: 1-5.
9. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356: 215-221.
10. Hall PA, McKee PH, Menage HD, Dover R, Lane DP. High levels of p53 protein in UV-irradiated normal human skin. Oncogene 1993; 8: 203-207.
11. Henry H, Thomas A, Shen Y, White E. Regulation of the mitochondrial checkpoint in p53-mediated apoptosis confers resistance to cell death. Oncogene 2002; 21: 748-760.
12. Sakahira H, Enari M, Nagata S. Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature 1998; 391: 96-99.
13. Kim SG, Ravi G, Hoffmann C, et al. p53-independent induction of Fas and apoptosis in leukemic cells by an adenosine derivative, C1-IB-MECA. Biochem Pharmacol 2002; 63: 871-880.
14. Akslen LA, Monstad SE, Larsen B, Straume O, Ogreid D. Frequent mutations of the p53 gene in cutaneous melanoma of the nodular type. Int J Cancer 1998; 79: 91-95.
15. Papp T, Jafari M, Schiffmann D. Lack of p53 mutations and loss of heterozygosity in non-cultured human melanocytic lesions. J Cancer Res Clin Oncol 1996; 122: 541-548.
16. Levin DB, Wilson K, Valadares de Amorim G, Webber J, Kenny P, Kusser W. Detection of p53 mutations in benign and dysplastic nevi. Cancer Res 1995; 55: 4278-4282.
17. Lane DP, Benchimol S. p53: oncogene or anti-oncogene? Genes Dev 1990; 4: 1-8.
18. Kaleem Z, Lind AC, Humphrey PA, et al. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas? Mod Pathol 2000; 13: 217-222.
19. Lassam NJ, From L, Kahn HJ. Overexpression of p53 is a late event in the development of malignant melanoma. Cancer Res 1993; 53: 2235-2238.
20. Bodner SM, Minna JD, Jensen SM, et al. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 1992; 7: 743-749.
21. Sparrow LE, Soong R, Dawkins HJ, Iacopetta BJ, Heenan PJ. p53 gene mutation and expression in naevi and melanomas. Melanoma Res 1995; 5: 93-100.
22. Poremba C, Yandell DW, Metze D, Kamanabrou D, Bocker W, Dockhorn-Dworniczak B. Immunohistochemical detection of p53 in melanomas with rare p53 gene mutations is associated with mdm-2 overexpression. Oncol Res 1995; 7: 331-339.
23. MacGeoch C, Barnes DM, Newton JA, et al. p53 protein detected by immunohistochemical staining is not always mutant. Dis Markers 1993; 11: 239-250.
24. Soengas MS, Capodieci P, Polsky D, et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001; 409: 207-211.
25. Jones PA. Cancer: death and methylation. Nature 2001; 409: 141, 143-144.
26. Selzer E, Schlagbauer-Wadl H, Okamoto I, Pehamberger H, Potter R, Jansen B. Expression of Bcl-2 family members in human melanocytes, in melanoma metastases and in melanoma cell lines. Melanoma Res 1998; 8: 197-203.
27. Huang DC, Strasser A. BH3-only proteins-essential initiators of apoptotic cell death. Cell 2000; 103: 839-842.
28. Jacobson MD, Burne JF, King MP, Miyashita T, Reed JC, Raff MC. Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA. Nature 1993; 361: 365-369.
29. Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997; 91: 479-489.
30. Yin XM, Oltvai ZN, Korsmeyer SJ. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 1994; 369: 321-323.
31. Bissonnette RP, Echeverri F, Mahboubi A, Green DR. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 1992; 359: 552-554.
32. Tang L, Tron VA, Reed JC, et al. Expression of apoptosis regulators in cutaneous malignant melanoma. Clin Cancer Res 1998; 4: 1865-1871.
33. Radhi JM. Malignant melanoma arising from nevi, p53, p16, and Bcl-2: expression in benign versus malignant components. J Cutan Med Surg 1999; 3: 293-297.
34. Zhang X, Xu Q, Saiki I. Quercetin inhibits the invasion and mobility of murine melanoma B16-BL6 cells through inducing apoptosis via decreasing Bcl-2 expression. Clin Exp Metastasis 2000; 18: 415-421.
35. Thomas WD, Zhang XD, Franco AV, Nguyen T, Hersey P. TNF-related apoptosis-inducing ligand-induced apoptosis of melanoma is associated with changes in mitochondrial membrane potential and perinuclear clustering of mitochondria. J Immunol 2000; 165: 5612-5620.
36. Yamada H, Tada-Oikawa S, Uchida A, Kawanishi S. TRAIL causes cleavage of bid by caspase-8 and loss of mitochondrial membrane potential resulting in apoptosis in BJAB cells. Biochem Biophys Res Commun 1999; 265: 130-133.
37. Reynolds JE, Yang T, Qian L, et al. Mcl-1, a member of the Bcl-2 family, delays apoptosis induced by c-Myc overexpression in Chinese hamster ovary cells. Cancer Res 1994; 54: 6348-6352.
38. Gottschalk AR, Boise LH, Thompson CB, Quintans J. Identification of immunosuppressant-induced apoptosis in a murine B-cell line and its prevention by bcl-x but not bcl-2. Proc Natl Acad Sci USA 1994; 91: 7350-7354.
39. Ogretmen B, Safa AR. Down-regulation of apoptosis-related bcl-2 but not bcl-xL or bax proteins in multidrug-resistant MCF-7/Adr human breast cancer cells. Int J Cancer 1996; 67: 608-614.
40. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104: 487-501.
41. Scaffidi C, Kirchhoff S, Krammer PH, Peter ME. Apoptosis signaling in lymphocytes. Curr Opin Immunol 1999; 11: 277-285.
42. Loetscher H, Gentz R, Zulauf M, et al. Recombinant 55-kDa tumor necrosis factor (TNF) receptor: stoichiometry of binding to TNF alpha and TNF beta and inhibition of TNF activity. J Biol Chem 1991; 266: 18 324-18 329.
43. Tartaglia LA, Ayres TM, Wong GH, Goeddel DV. A novel domain within the 55 kd TNF receptor signals cell death. Cell 1993; 74: 845-853.
44. Carrel S, Hartmann F, Salvi S, Albrecht H, Schreyer M, Rimoldi D. Expression of type A and B tumor necrosis factor (TNF) receptors on melanoma cells can be regulated by dbc-AMP and IFN gamma. Int J Cancer 1995; 62: 76-83.
45. Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 1998; 161: 2833-2840.
46. Bakker TR, Reed D, Renno T, Jongeneel CV. Efficient adenoviral transfer of NF-kappaB inhibitor sensitizes melanoma to tumor necrosis factor-mediated apoptosis. Int J Cancer 1999; 80: 320-323.
47. Bazzoni F, Regalia E. Triggering of antitumor activity through melanoma-specific transduction of a constitutively active tumor necrosis factor (TNF) R1 chimeric receptor in the absence of TNF-alpha. Cancer Res 2001; 61: 1050-1057.
48. Arch RH, Gedrich RW, Thompson CB. Translocation of TRAF proteins regulates apoptotic threshold of cells. Biochem Biophys Res Commun 2000; 272: 936-945.
49. Ivanov VN, Kehrl JH, Ronai Z. Role of TRAF2/GCK in melanoma sensitivity to UV-induced apoptosis. Oncogene 2000; 19: 933-942.
50. Pombo CM, Kehrl JH, Sanchez I, et al. Activation of the SAPK pathway by the human STE20 homologue germinal centre kinase. Nature 1995; 377: 750-754.
51. Malinin NL, Boldin MP, Kovalenko AV, Wallach D. MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1. Nature 1997; 385: 540-544.
52. Hofmann K, Bucher P, Tschopp J. The CARD domain: a new apoptotic signalling motif. Trends Biochem Sci 1997; 22: 155-156.
53. Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 1999; 11: 255-260.
54. Zhang XD, Nguyen T, Thomas WD, Sanders JE, Hersey P. Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEBS Lett 2000; 482: 193-199.
55. Zhang XD, Franco A, Myers K, Gray C, Nguyen T, Hersey P. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res 1999; 59: 2747-2753.
56. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997; 7: 813-820.
57. Schneider P, Thome M, Burns K, et al. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity 1997; 7: 831-836.
58. Nguyen T, Thomas W, Zhang XD, Gray C, Hersey P. Immunologically-mediated tumour cell apoptosis: the role of TRAIL in T cell and cytokine-mediated responses to melanoma. Forum (Genova) 2000; 10: 243-252.
59. Thomas WD, Hersey P. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells. J Immunol 1998; 161: 2195-2200.
60. Kim K, Fisher MJ, Xu SQ, el-Deiry WS. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res 2000; 6: 335-346.
61. Franco AV, Zhang XD, Van Berkel E, et al. The role of NF-kappa B in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells. J Immunol 2001; 166: 5337-5345.
62. Steffan NM, Bren GD, Frantz B, Tocci MJ, O'Neill EA, Paya CV. Regulation of IkB alpha phosphorylation by PKC- and Ca(2+)-dependent signal transduction pathways. J Immunol 1995; 155: 4685-4691.
63. Novak U, Cocks BG, Hamilton JA. A labile repressor acts through the NFkB-like binding sites of the human urokinase gene. Nucleic Acids Res 1991; 19: 3389-3393.
64. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998; 281: 1680-1683.
65. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169-1178.
66. Raisova M, Bektas M, Wieder T, et al. Resistance to CD95/Fas-induced and ceramide-mediated apoptosis of human melanoma cells is caused by a defective mitochondrial cytochrome c release. FEBS Lett 2000; 473: 27-32.
67. Gross A, Yin XM, Wang K, et al. Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J Biol Chem 1999; 274: 1156-1163.
68. Rivoltini L, Radrizzani M, Accomero P, et al. Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing. J Immunol 1998; 161: 1220-1230.
69. Hahne M, Rimoldi D, Schroter M, et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996; 274: 1363-1366.
70. Shin MS, Park WS, Kim SY, et al. Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma. Am J Pathol 1999; 154: 1785-1791.
71. Aragane Y, Maeda A, Cui CY, Tezuka T, Kaneda Y, Schwarz T. Inhibition of growth of melanoma cells by CD95 (Fas/APO-1) gene transfer in vivo. J Invest Dermatol 2000; 115: 1008-1014.
72. Soubrane C, Mouawad R, Antoine EC, Verola O, Gil-Delgado M, Khayat D. A comparative study of Fas and Fas-ligand expression during melanoma progression. Br J Dermatol 2000; 143: 307-312.
73. Raisova M, Hossini AM, Eberle J, et al. The Bax/Bcl-2 ratio determines the susceptibility of human melanoma cells to CD95/Fas-mediated apoptosis. J Invest Dermatol 2001; 117: 333-340.
74. Walker PR, Saas P, Dietrich PY. Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. J Immunol 1997; 158: 4521-4524.
75. Mouawad R, Khayat D, Soubrane C. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in advanced melanoma. Melanoma Res 2000; 10: 461-467.
76. Ariza ME, Broome-Powell M, Lahti JM, Kidd VJ, Nelson MA. Fas-induced apoptosis in human malignant melanoma cell lines is associated with the activation of the p34(cdc2)-related PITSLRE protein kinases. J Biol Chem 1999; 274: 28 505-28 513.
77. Shi L, Nishioka WK, Th'ng J, Bradbury EM, Litchfield DW, Greenberg AH. Premature p34cdc2 activation required for apoptosis. Science 1994; 263: 1143-1145.
78. Nelson MA, Ariza ME, Yang JM, et al. Abnormalities in the p34cdc2-related PITSLRE protein kinase gene complex (CDC2L) on chromosome band 1p36 in melanoma. Cancer Genet Cytogenet 1999; 108: 91-99.
79. Mecchia M, Matarrese P, Malorni W, et al. Type I consensus interferon (CIFN) gene transfer into human melanoma cells up-regulates p53 and enhances cisplatin-induced apoptosis: implications for new therapeutic strategies with IFN-alpha. Gene Ther 2000; 7: 167-179.
80. Chawla-Sarkar M, Leaman DW, Borden EC. Preferential induction of apoptosis by interferon (ifn)-beta compared with ifn-alpha2: correlation with trail/apo21 induction in melanoma cell lines. Clin Cancer Res 2001; 7: 1821-1831.
81. Xie K, Wang Y, Huang S, et al. Nitric oxide-mediated apoptosis of K-1735 melanoma cells is associated with downregulation of Bcl-2. Oncogene 1997; 15: 771-779.
82. Ugurel S, Seiter S, Rappl G, Stark A, Tilgen W, Reinhold U. Heterogenous susceptibility to CD95-induced apoptosis in melanoma cells correlates with bcl-2 and bcl-x expression and is sensitive to modulation by interferon-gamma. Int J Cancer 1999; 82: 727-736.
83. Lassam N, Bickford S. Loss of c-kit expression in cultured melanoma cells. Oncogene 1992; 7: 51-56.
84. Zakut R, Perlis R, Eliyahu S, et al. KIT ligand (mast cell growth factor) inhibits the growth of KIT-expressing melanoma cells. Oncogene 1993; 8: 2221-2229.
85. Huang S, Jean D, Luca M, Tainsky MA, Bar-Eli M. Loss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis. Embo J 1998; 17: 4358-4369.
86. Luca MR, Bar-Eli M. Molecular changes in human melanoma metastasis. Histol Histopathol 1998; 13: 1225-1231.
87. Natali PG, Nicotra MR, Winkler AB, Cavaliere R, Bigotti A, Ullrich A. Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor. Int J Cancer 1992; 52: 197-201.
88. D'Agnano I, Valentini A, Fornari C, et al. Myc down-regulation induces apoptosis in M14 melanoma cells by increasing p27(kip1) levels. Oncogene 2001; 20: 2814-2825.
89. Evan GI, Wyllie AH, Gilbert CS, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992; 69: 119-128.
90. Kimura S, Maekawa T, Hirakawa K, Murakami A, Abe T. Alterations of c-myc expression by antisense oligodeoxynucleotides enhance the induction of apoptosis in HL-60 cells. Cancer Res 1995; 55: 1379-1384.
91. Evan G, Littlewood T. A matter of life and cell death. Science 1998; 281: 1317-1322.
92. Citro, G, D'Agnano I, Leonetti C, et al. c-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice. Cancer Res 1998; 58: 283-289.
93. Leonetti C, D'Agnano I, Lozupone F, et al. Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and in mice. J Natl Cancer Inst 1996; 88: 419-429.
94. Leonetti C, Biroccio A, Candiloro A, et al. Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin. Clin Cancer Res 1999; 5: 2588-2595.
95. Biroccio A, Benassi B, Amodei S, Gabellini C, Del Bufalo D, Zupi G. c-Myc down-regulation increases susceptibility to cisplatin through reactive oxygen species-mediated apoptosis in M14 human melanoma cells. Mol Pharmacol 2001; 60: 174-182.
96. Kasof GM, Gomes BC. Livin, a novel inhibitor of apoptosis protein family member. J Biol Chem 2001; 276: 3238-3246.
97. Deveraux QL, Reed JC. IAP family proteins: suppressors of apoptosis. Genes Dev 1999; 13: 239-252.
98. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-921.
99. Tamm I, Wang Y, Sausville E, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998; 58: 5315-5320.
100. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998; 396: 580-584.
101. Grossman D, McNiff JM, Li F, Altieri DC. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 1999; 113: 1076-1081.
102. Grossman D, Kim PJ, Schechner JS, Altieri DC. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci USA 2001; 98: 635-640.
103. Vucic D, Stennicke HR, Pisabarro MT, Salvesen GS, Dixit VM. ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr Biol 2000; 10: 1359-1366.
104. Vucic D, Deshayes K, Ackerly H, et al. SMAC negatively regulates the anti-apoptotic activity of melanoma inhibitor of apoptosis (ML-IAP). J Biol Chem 2002; 277: 12 275-12 279.
105. Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 1989; 86: 2863-2867.
106. Sakurai T, Yanagisawa M, Takuwa Y, et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 1990; 348: 732-735.
107. Sugawara F, Ninomiya H, Okamoto Y, et al. Endothelin-1-induced mitogenic responses of Chinese hamster ovary cells expressing human endothelin A: the role of a wortmannin-sensitive signaling pathway. Mol Pharmacol 1996; 49: 447-457.
108. Okazawa M, Shiraki T, Ninomiya H, Kobayashi S, Masaki T. Endothelin-induced apoptosis of A375 human melanoma cells. J Biol Chem 1998; 273: 12 584-12 592.
109. Reid K, Turnley AM, Maxwell GD, et al. Multiple roles for endothelin in melanocyte development: regulation of progenitor number and stimulation of differentiation. Development 1996; 122: 3911-3919.
110. Yohn JJ, Smith C, Stevens T, et al. Human melanoma cells express functional endothelin-1 receptors. Biochem Biophys Res Commun 1994; 201: 449-457.
111. Eberle J, Weitmann S, Thieck O, Pech H, Paul M, Orfanos CE. Downregulation of endothelin B receptor in human melanoma cell lines parallel to differentiation genes. J Invest Dermatol 1999; 112: 925-932.
112. Kikuchi K, Nakagawa H, Kadono T, et al. Decreased ET(B) receptor expression in human metastatic melanoma cells. Biochem Biophys Res Commun 1996; 219: 734-739.
113. Lahav R, Heffner G, Patterson PH. An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo. Proc Natl Acad Sci USA 1999; 96: 11 496-11 500.
114. Mason MD, Allman R, Quibell M. Adhesion molecules in melanoma: more than just superglue? J R Soc Med 1996; 89: 393-395.
115. Williams JA. Disintegrins: RGD-containing proteins which inhibit cell/matrix interactions (adhesion) and cell/cell interactions (aggregation) via the integrin receptors. Pathol Biol (Paris) 1992; 40: 813-821.
116. Gehlsen KR, Davis GE, Sriramarao P. Integrin expression in human melanoma cells with differing invasive and metastatic properties. Clin Exp Metastasis 1992; 10: 111-120.
117. Morales-Ducret CR, van de Rijn M, Smoller BR. bcl-2 expression in melanocytic nevi: insights into the biology of dermal maturation. Arch Dermatol 1995; 131: 915-918.
118. Sprecher E, Bergman R, Meilick A, et al. Apoptosis, Fas and Fas-ligand expression in melanocytic tumors. J Cutan Pathol 1999; 26: 72-77.
119. Boni R, Wellmann A, Man YG, Hofbauer G, Brinkmann U. Expression of the proliferation and apoptosis-associated CAS protein in benign and malignant cutaneous melanocytic lesions. Am J Dermatopathol 1999; 21: 125-128.
120. Haapajarvi T, Pitkanen K, Laiho M. Human melanoma cell line UV responses show independency of p53 function. Cell Growth Differ 1999; 10: 163-171.
121. Ivanov VN, Ronai Z. p38 protects human melanoma cells from UV-induced apoptosis through down-regulation of NF-kappaB activity and Fas expression. Oncogene 2000; 19: 3003-3012.